Cargando…

Autoantibodies in cryptogenic fibrosing alveolitis

The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based used...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Suveer, du Bois, Ron
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59568/
https://www.ncbi.nlm.nih.gov/pubmed/11686865
http://dx.doi.org/10.1186/rr38
_version_ 1782120074515054592
author Singh, Suveer
du Bois, Ron
author_facet Singh, Suveer
du Bois, Ron
author_sort Singh, Suveer
collection PubMed
description The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based used novel cloning and serum screening technologies in order to identify new public and private autoantibodies in sera from 12 patients with CFA. Largely negative conclusions were drawn from that study. However, we suggest that the prevalence of autoantibodies may have been underestimated, that the study was timely and that this approach is worth pursuing further.
format Text
id pubmed-59568
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-595682001-11-06 Autoantibodies in cryptogenic fibrosing alveolitis Singh, Suveer du Bois, Ron Respir Res Commentary The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based used novel cloning and serum screening technologies in order to identify new public and private autoantibodies in sera from 12 patients with CFA. Largely negative conclusions were drawn from that study. However, we suggest that the prevalence of autoantibodies may have been underestimated, that the study was timely and that this approach is worth pursuing further. BioMed Central 2001 2001-02-21 /pmc/articles/PMC59568/ /pubmed/11686865 http://dx.doi.org/10.1186/rr38 Text en Copyright © 2001 BioMed Central Ltd
spellingShingle Commentary
Singh, Suveer
du Bois, Ron
Autoantibodies in cryptogenic fibrosing alveolitis
title Autoantibodies in cryptogenic fibrosing alveolitis
title_full Autoantibodies in cryptogenic fibrosing alveolitis
title_fullStr Autoantibodies in cryptogenic fibrosing alveolitis
title_full_unstemmed Autoantibodies in cryptogenic fibrosing alveolitis
title_short Autoantibodies in cryptogenic fibrosing alveolitis
title_sort autoantibodies in cryptogenic fibrosing alveolitis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59568/
https://www.ncbi.nlm.nih.gov/pubmed/11686865
http://dx.doi.org/10.1186/rr38
work_keys_str_mv AT singhsuveer autoantibodiesincryptogenicfibrosingalveolitis
AT duboisron autoantibodiesincryptogenicfibrosingalveolitis